CEA-regulated Oncolytic Virus Anticancer Therapy: A Promising Strategy
for Rare Solid Tumors

doi:10.2174/1568009622666220202143852

摘要

背景：由于临床需求未得到满足、治疗选择有限和预后不良，罕见实体瘤引起了更多关注。作为研究最深入的肿瘤标志物，癌胚抗原（CEA）不仅可以在各种常见的实体瘤中过表达，而且在几种罕见的实体瘤中也可以过表达。溶瘤病毒疗法在过去几十年中取得了优异的抗癌效果。由于CEA在某些肿瘤组织中特异性高表达，而在正常组织中不存在，因此CEA已被应用于提高基因表达的肿瘤特异性。方法：回顾了 CEA 在罕见实体瘤中的表达和 CEA 调节的溶瘤病毒治疗的研究。结果：我们展示了 CEA 过表达的罕见实体瘤的类型。升高的血清 CEA 水平可以指示诊断、手术或系统治疗的反应、远端转移、复发和生存。由于肿瘤特异性高，CEA 调节的 OA 疗法在临床前试验中已证明对常见的 CEA 阳性肿瘤具有惊人的抗肿瘤作用。结论：这些数据表明，CEA 可能是几种罕见实体瘤的诊断和预后生物标志物。我们提出了这样的假设，即 CEA 调节的溶瘤病毒疗法可能是 CEA 阳性罕见实体瘤的一种有前途的治疗策略。

关键词: 癌胚抗原、溶瘤病毒、罕见、实体瘤、治疗、过表达。

« Previous Next »

图形摘要

[1] 
Kang, S. Carcinoembryonic antigen, the most accessible test for predicting colorectal cancer prognosis: Exploring alternative roles. Ann. Coloproctol.,  2021, 37(3), 129-130.
[http://dx.doi.org/10.3393/ac.2021.00493.0070] [PMID: 34233114] 
[2] 
Wang, S.; Huang, H.Y.; Wu, D.; Fang, H.; Ying, J.; Bai, Y.; Yu, Y.; Fang, Y.; Jiang, N.; Sun, C.; Yu, A.; Fan, Q.; Xing, S.; Ni, Y.; Zhang, W.; Wu, C.; Ji, X.; Wang, H.; Guo, Y.; Tang, Q.; Wang, Y.; Tang, Y.; Li, N. Platform study of genotyping-guided precision medicine for rare solid tumours: A study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. BMJ Open,  2021, 11(6), e044543.
[http://dx.doi.org/10.1136/bmjopen-2020-044543] [PMID: 34083331] 
[3] 
Gold, P.; Freedman, S.O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med.,  1965, 122(3), 467-81.
[4] 
Hensel, J.A.; Khattar, V.; Ashton, R.; Ponnazhagan, S. Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity. Mol. Ther. Oncolytics,  2018, 12, 41-48.
[http://dx.doi.org/10.1016/j.omto.2018.12.004] [PMID: 30666318] 
[5] 
Chen, C.H.; Hsieh, M.C.; Lai, C.C.; Yeh, C.Y.; Chen, J.S.; Hsieh, P.S.; Chiang, J.M.; Tsai, W.S.; Tang, R.; Changchien, C.R.; Wang, J.Y. Lead time of carcinoembryonic antigen elevation in the postoperative follow-up of colorectal cancer did not affect the survival rate after recurrence. Int. J. Colorectal Dis.,  2010, 25(5), 567-571.
[http://dx.doi.org/10.1007/s00384-010-0889-6] [PMID: 20162425] 
[6] 
Chiaravalloti, A.; Fiorentini, A.; Palombo, E.; Rinino, D.; Lacanfora, A.; Danieli, R.; Di Russo, C.; Di Biagio, D.; Squillaci, E.; Schillaci, O. Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection. Oncol. Lett.,  2016, 12(5), 4209-4213.
[http://dx.doi.org/10.3892/ol.2016.5143] [PMID: 27895793] 
[7] 
Blumenthal, R.D.; Leon, E.; Hansen, H.J.; Goldenberg, D.M. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer,  2007, 7, 2.
[http://dx.doi.org/10.1186/1471-2407-7-2] [PMID: 17201906] 
[8] 
Marshall, J. Carcinoembryonic antigen-based vaccines. Semin. Oncol.,  2003, 30(3)(Suppl. 8), 30-36.
[http://dx.doi.org/10.1016/S0093-7754(03)00233-1] [PMID: 12881810] 
[9] 
Hall, C.; Clarke, L.; Pal, A.; Buchwald, P.; Eglinton, T.; Wakeman, C.; Frizelle, F. A Review of the role of carcinoembryonic antigen in clinical practice. Ann. Coloproctol.,  2019, 35(6), 294-305.
[http://dx.doi.org/10.3393/ac.2019.11.13] [PMID: 31937069] 
[10] 
Pesonen, S.; Kangasniemi, L.; Hemminki, A. Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data. Mol. Pharm.,  2011, 8(1), 12-28.
[http://dx.doi.org/10.1021/mp100219n] [PMID: 21126047] 
[11] 
Turnbull, S.; West, E.J.; Scott, K.J.; Appleton, E.; Melcher, A.; Ralph, C. Evidence for oncolytic virotherapy: Where have we got to and where are we going? Viruses,  2015, 7(12), 6291-6312.
[http://dx.doi.org/10.3390/v7122938] [PMID: 26633468] 
[12] 
Zhou, X.; Xie, G.; Wang, S.; Wang, Y.; Zhang, K.; Zheng, S.; Chu, L.; Xiao, L.; Yu, Y.; Zhang, Y.; Liu, X. Potent and specific antitumor effect for colorectal cancer by CEA and Rb double regulated oncolytic adenovirus harboring ST13 gene. PLoS One,  2012, 7(10), e47566.
[http://dx.doi.org/10.1371/journal.pone.0047566] [PMID: 23077639] 
[13] 
Zhang, R.; Zhang, X.; Ma, B.; Xiao, B.; Huang, F.; Huang, P.; Ying, C.; Liu, T.; Wang, Y. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer. Cancer Gene Ther.,  2016, 23(6), 168-177.
[http://dx.doi.org/10.1038/cgt.2016.11] [PMID: 27080225] 
[14] 
Xiao, B.; Ying, C.; Chen, Y.; Huang, F.; Wang, B.; Fang, H.; Guo, W.; Liu, T.; Zhou, X.; Huang, B.; Liu, X.; Wang, Y. Doxorubicin hydrochloride enhanced antitumour effect of CEA-regulated oncolytic virotherapy in live cancer cells and a mouse model. J. Cell. Mol. Med.,  2020, 24(22), 13431-13439.
[http://dx.doi.org/10.1111/jcmm.15966] [PMID: 33251723] 
[15] 
Wells, S.A., Jr; Asa, S.L.; Dralle, H.; Elisei, R.; Evans, D.B.; Gagel, R.F.; Lee, N.; Machens, A.; Moley, J.F.; Pacini, F.; Raue, F.; Frank-Raue, K.; Robinson, B.; Rosenthal, M.S.; Santoro, M.; Schlumberger, M.; Shah, M.; Waguespack, S.G. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid,  2015, 25(6), 567-610.
[http://dx.doi.org/10.1089/thy.2014.0335] [PMID: 25810047] 
[16] 
Romero-Lluch, A.R.; Cuenca-Cuenca, J.I.; Guerrero-Vázquez, R.; Martínez-Ortega, A.J.; Tirado-Hospital, J.L.; Borrego-Dorado, I.; Navarro-González, E. Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging,  2017, 44(12), 2004-2013.
[http://dx.doi.org/10.1007/s00259-017-3759-4] [PMID: 28646462] 
[17] 
Turkdogan, S.; Forest, V.I.; Hier, M.P.; Tamilia, M.; Florea, A.; Payne, R.J. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer. J. Otolaryngol. Head Neck Surg.,  2018, 47(1), 55.
[http://dx.doi.org/10.1186/s40463-018-0303-x] [PMID: 30223887] 
[18] 
Hajje, G.; Borget, I.; Leboulleux, S.; Chougnet, C.; Al Ghuzlan, A.; Mirghani, H.; Caramella, C.; Hartl, D.; Schlumberger, M.; Baudin, E. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy. Eur. J. Endocrinol.,  2012, 168(2), 113-118.
[http://dx.doi.org/10.1530/EJE-12-0771] [PMID: 23093698] 
[19] 
Meijer, J.A.; le Cessie, S.; van den Hout, W.B.; Kievit, J.; Schoones, J.W.; Romijn, J.A.; Smit, J.W. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: A structured meta-analysis. Clin. Endocrinol. (Oxf.),  2010, 72(4), 534-542.
[http://dx.doi.org/10.1111/j.1365-2265.2009.03666.x] [PMID: 19563448] 
[20] 
Aparicio, T.; Zaanan, A.; Svrcek, M.; Laurent-Puig, P.; Carrere, N.; Manfredi, S.; Locher, C.; Afchain, P. Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. Dig. Liver Dis.,  2014, 46(2), 97-104.
[http://dx.doi.org/10.1016/j.dld.2013.04.013] [PMID: 23796552] 
[21] 
Bilimoria, K.Y.; Bentrem, D.J.; Wayne, J.D.; Ko, C.Y.; Bennett, C.L.; Talamonti, M.S. Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years. Ann. Surg.,  2009, 249(1), 63-71.
[http://dx.doi.org/10.1097/SLA.0b013e31818e4641] [PMID: 19106677] 
[22] 
Zaanan, A.; Costes, L.; Gauthier, M.; Malka, D.; Locher, C.; Mitry, E.; Tougeron, D.; Lecomte, T.; Gornet, J.M.; Sobhani, I.; Moulin, V.; Afchain, P.; Taïeb, J.; Bonnetain, F.; Aparicio, T. Chemotherapy of advanced small-bowel adenocarcinoma: A multicenter AGEO study. Ann. Oncol.,  2010, 21(9), 1786-1793.
[http://dx.doi.org/10.1093/annonc/mdq038] [PMID: 20223786] 
[23] 
Wang, Z.; Ding, Z.; Huang, S.; Zhong, S. Experience in clinical diagnosis and treatment of duodenal tumors. Mol. Clin. Oncol.,  2016, 5(6), 731-739.
[http://dx.doi.org/10.3892/mco.2016.1061] 
[24] 
Mao, K.; Jiang, W.; Liu, J.; Wang, J. Incidence of subsequent cholangiocarcinomas after another malignancy: Trends in a population-based study. Medicine (Baltimore),  2015, 94(8), e596.
[http://dx.doi.org/10.1097/MD.0000000000000596] [PMID: 25715268] 
[25] 
DeOliveira, M.L.; Cunningham, S.C.; Cameron, J.L.; Kamangar, F.; Winter, J.M.; Lillemoe, K.D. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg,  2007, 245(5), 755-62.
[http://dx.doi.org/10.1097/01.sla.0000251366.62632.d3] 
[26] 
Loosen, S.H.; Roderburg, C.; Kauertz, K.L.; Koch, A.; Vucur, M.; Schneider, A.T. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci. Rep.,  2017, 7(1), 16975.
[http://dx.doi.org/10.1038/s41598-017-17175-7] 
[27] 
Chen, S.; Chen, Y.; Yang, J.; Yang, W.; Weng, H.; Li, H.; Liu, D. Primary mucoepidermoid carcinoma of the esophagus. J. Thorac. Oncol.,  2011, 6(8), 1426-1431.
[http://dx.doi.org/10.1097/JTO.0b013e31821cfb96] [PMID: 21587086] 
[28] 
Hagiwara, N.; Tajiri, T.; Tajiri, T.; Miyashita, M.; Sasajima, K.; Makino, H.; Matsutani, T.; Tsuchiya, Y.; Takubo, K.; Yamashita, K. Biological behavior of mucoepidermoid carcinoma of the esophagus. J. Nippon Med. Sch.,  2003, 70(5), 401-407.
[http://dx.doi.org/10.1272/jnms.70.401] [PMID: 14578940] 
[29] 
Benedix, F; Reimer, A; Gastinger, I; Mroczkowski, P; Lippert, H; Kube, R. Primary appendiceal carcinoma--epidemiology, surgery and survival: Results of a German multi-center study. Eur J Surg Oncol,  2010, 36(8), 763-71.
[30] 
Carmignani, C.P.; Hampton, R.; Sugarbaker, C.E.; Chang, D.; Sugarbaker, P.H. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J. Surg. Oncol.,  2004, 87(4), 162-166.
[http://dx.doi.org/10.1002/jso.20107] [PMID: 15334630] 
[31] 
Jang, J.Y.; Choi, N.; Ko, Y.H.; Chung, M.K.; Son, Y.I.; Baek, C.H.; Baek, K.H.; Jeong, H.S. Treatment outcomes in metastatic and localized high-grade salivary gland cancer: High chance of cure with surgery and post-operative radiation in T1-2 N0 high- grade salivary gland cancer. BMC Cancer,  2018, 18(1), 672.
[http://dx.doi.org/10.1186/s12885-018-4578-0] [PMID: 29925355] 
[32] 
He, H.; Chen, G.; Zhou, L.; Liu, Y. A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland. J. Cancer Res. Clin. Oncol.,  2009, 135(10), 1315-1321.
[http://dx.doi.org/10.1007/s00432-009-0572-x] [PMID: 19322585] 
[33] 
Metze, D.; Luger, T.A. Ultrastructural localization of Carcinoembryonic Antigen (CEA) glycoproteins and Epithelial Membrane Antigen (EMA) in normal and neoplastic sweat glands. J. Cutan. Pathol.,  1996, 23(6), 518-29.
[34] 
Latteri, S.; Catania, V.E.; Malaguarnera, G.; Peri, A.; Bertino, G.; Frazzetto, G.; Borzì, A.M.; Biondi, A.; Perrotta, R.E.; Malaguarnera, M. Carcinoembryonic antigen serum levels in nonmelanoma skin cancer. Biomedicines,  2018, 6(1), 24.
[http://dx.doi.org/10.3390/biomedicines6010024] [PMID: 29473860] 
[35] 
Ramezani, M; Mohamadzaheri, E; Khazaei, S; Najafi, F; Vaisi-Raygani, A; Rahbar, M Comparison of EMA, CEA, CD10 and Bcl-2 biomarkers by immunohistochemistry in squamous cell carcinoma and basal cell carcinoma of the skin. Asian Pac J Cancer Prev,  2016, 17(3), 1379-83.
[36] 
Schrewe, H.; Thompson, J.; Bona, M.; Hefta, L.J.; Maruya, A.; Hassauer, M.; Shively, J.E.; von Kleist, S.; Zimmermann, W. Cloning of the complete gene for carcinoembryonic antigen: Analysis of its promoter indicates a region conveying cell type-specific expression. Mol. Cell. Biol.,  1990, 10(6), 2738-2748.
[http://dx.doi.org/10.1128/mcb.10.6.2738-2748.1990] [PMID: 2342461] 
[37] 
Hauck, W.; Stanners, C.P. Transcriptional regulation of the carcinoembryonic antigen gene. Identification of regulatory elements and multiple nuclear factors. J. Biol. Chem.,  1995, 270(8), 3602-3610.
[http://dx.doi.org/10.1074/jbc.270.8.3602] [PMID: 7876096] 
[38] 
Richards, C.A.; Austin, E.A.; Huber, B.E. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther.,  1995, 6(7), 881-893.
[http://dx.doi.org/10.1089/hum.1995.6.7-881] [PMID: 7578407] 
[39] 
Li, Y.; Chen, Y.; Dilley, J.; Arroyo, T.; Ko, D.; Working, P.; Yu, D.C. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol. Cancer Ther.,  2003, 2(10), 1003-1009.
[PMID: 14578465] 

Rights & Permissions Print Cite

Article Metrics

21

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1568009622666220202143852	Print ISSN 1568-0096
Publisher Name Bentham Science Publisher	Online ISSN 1873-5576

当代肿瘤药物靶点

CEA 调节的溶瘤病毒抗癌治疗：治疗罕见实体瘤的有希望的策略

摘要

图形摘要

当代肿瘤药物靶点

CEA 调节的溶瘤病毒抗癌治疗：治疗罕见实体瘤的有希望的策略

摘要 Play Pause

图形摘要

Related Journals

Related Books

Related Articles

摘要